Do analysts prefer ALDX or PLRZ?

Aldeyra Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 255.99%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ALDX or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is ALDX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Polyrizon N/A N/A N/A

Do analysts prefer PLRZ or VRCA?

Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 183.65%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings & valuation, PLRZ or VRCA?

Polyrizon has higher earnings, but lower revenue than Verrica Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Verrica Pharmaceuticals $35.58M 2.47 -$17.89M -$1.67 N/A

Do analysts prefer HRTX or PLRZ?

Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 430.50%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, HRTX or PLRZ?

Polyrizon has lower revenue, but higher earnings than Heron Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heron Therapeutics $150.71M 0.47 -$20.19M -$0.18 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Do analysts prefer CGTX or PLRZ?

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 218.98%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CGTX or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is CGTX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -49.97% -39.34% Polyrizon N/A N/A N/A

Do analysts prefer PLRZ or PYPD?

PolyPid has a consensus target price of $11.33, indicating a potential upside of 132.34%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PolyPid 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has stronger earnings & valuation, PLRZ or PYPD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A PolyPid N/A N/A -$34.17M -$1.91 N/A

Is PLRZ or PYPD more profitable?

Polyrizon's return on equity of 0.00% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A PolyPid N/A -241.96% -126.91%

Polyrizon (PLRZ) Competitors

$11.11 -0.48 (-4.15%)

As of 11:33 AM Eastern

Compare

PLRZ vs. ALDX, VRCA, HRTX, CGTX, and PYPD

Should you buy Polyrizon stock or one of its competitors? MarketBeat compares Polyrizon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polyrizon include Aldeyra Therapeutics (ALDX), Verrica Pharmaceuticals (VRCA), Heron Therapeutics (HRTX), Cognition Therapeutics (CGTX), and PolyPid (PYPD). These companies are all part of the "pharmaceuticals" industry.

How does Polyrizon compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Aldeyra Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 255.99%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aldeyra Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Polyrizon. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.00 beat Aldeyra Therapeutics' score of -0.66 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Negative
Polyrizon	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Polyrizon	N/A	N/A	N/A

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aldeyra Therapeutics beats Polyrizon on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Verrica Pharmaceuticals?

Polyrizon (NASDAQ:PLRZ) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 183.65%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Polyrizon has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.22 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Neutral
Verrica Pharmaceuticals	Neutral

Polyrizon has higher earnings, but lower revenue than Verrica Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Verrica Pharmaceuticals	$35.58M	2.47	-$17.89M	-$1.67	N/A

Polyrizon has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Polyrizon's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%

Summary

Verrica Pharmaceuticals beats Polyrizon on 8 of the 13 factors compared between the two stocks.

How does Polyrizon compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

80.0% of Heron Therapeutics shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Heron Therapeutics had 9 more articles in the media than Polyrizon. MarketBeat recorded 9 mentions for Heron Therapeutics and 0 mentions for Polyrizon. Heron Therapeutics' average media sentiment score of 0.78 beat Polyrizon's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Polyrizon	Neutral

Polyrizon has lower revenue, but higher earnings than Heron Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	0.47	-$20.19M	-$0.18	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market.

Polyrizon has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Polyrizon's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Polyrizon	N/A	N/A	N/A

Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 430.50%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Heron Therapeutics beats Polyrizon on 9 of the 13 factors compared between the two stocks.

How does Polyrizon compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Cognition Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, indicating that its stock price is 250% less volatile than the broader market.

In the previous week, Cognition Therapeutics had 4 more articles in the media than Polyrizon. MarketBeat recorded 4 mentions for Cognition Therapeutics and 0 mentions for Polyrizon. Cognition Therapeutics' average media sentiment score of 0.50 beat Polyrizon's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Polyrizon	Neutral

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 218.98%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-49.97%	-39.34%
Polyrizon	N/A	N/A	N/A

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cognition Therapeutics beats Polyrizon on 8 of the 11 factors compared between the two stocks.

How does Polyrizon compare to PolyPid?

Polyrizon (NASDAQ:PLRZ) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Polyrizon's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
PolyPid	N/A	-241.96%	-126.91%

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

PolyPid has a consensus target price of $11.33, indicating a potential upside of 132.34%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, PolyPid had 1 more articles in the media than Polyrizon. MarketBeat recorded 1 mentions for PolyPid and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.00 equaled PolyPid'saverage media sentiment score.

Company	Overall Sentiment
Polyrizon	Neutral
PolyPid	Neutral

Summary

PolyPid beats Polyrizon on 7 of the 10 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.93M	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	N/A	788.46	269.91	24.87
Price / Sales	N/A	969.81	654.69	108.21
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.85	10.37	11.40	6.45
Net Income	-$3.34M	$2.77B	$3.45B	$347.50M
7 Day Performance	4.90%	2.26%	3.66%	3.77%
1 Month Performance	-24.17%	-1.28%	-0.49%	-0.40%
1 Year Performance	68.32%	191.26%	77.51%	23.55%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	0.4373 of 5 stars	$11.11 -4.2%	N/A	+65.5%	$22.93M	N/A	N/A	N/A	Gap Down
ALDX Aldeyra Therapeutics	3.1114 of 5 stars	$1.56 -2.8%	$5.50 +253.7%	-70.5%	$93.80M	N/A	N/A	10	Positive News Earnings Report
VRCA Verrica Pharmaceuticals	2.0432 of 5 stars	$5.46 +3.7%	$14.50 +165.8%	-20.0%	$93.73M	$37.16M	N/A	40
HRTX Heron Therapeutics	2.0734 of 5 stars	$0.49 -0.7%	$2.50 +406.1%	-62.8%	$93.50M	$154.90M	N/A	300	News Coverage Earnings Report Analyst Upgrade Gap Down
CGTX Cognition Therapeutics	2.2536 of 5 stars	$0.91 -1.2%	$3.33 +268.3%	+43.1%	$81.53M	N/A	N/A	20	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors

PLRZ vs. ALDX, VRCA, HRTX, CGTX, and PYPD

How does Polyrizon compare to Aldeyra Therapeutics?

Summary

How does Polyrizon compare to Verrica Pharmaceuticals?

Summary

How does Polyrizon compare to Heron Therapeutics?

Summary

How does Polyrizon compare to Cognition Therapeutics?

Summary

How does Polyrizon compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polyrizon (PLRZ) Competitors

PLRZ vs. ALDX, VRCA, HRTX, CGTX, and PYPD

How does Polyrizon compare to Aldeyra Therapeutics?

Do analysts prefer ALDX or PLRZ?

Which has more risk and volatility, ALDX or PLRZ?

Does the media prefer ALDX or PLRZ?

Which has preferable earnings & valuation, ALDX or PLRZ?

Is ALDX or PLRZ more profitable?

Do institutionals and insiders believe in ALDX or PLRZ?

Summary

How does Polyrizon compare to Verrica Pharmaceuticals?

Do institutionals & insiders hold more shares of PLRZ or VRCA?

Do analysts prefer PLRZ or VRCA?

Which has more risk & volatility, PLRZ or VRCA?

Does the media refer more to PLRZ or VRCA?

Which has higher earnings & valuation, PLRZ or VRCA?

Is PLRZ or VRCA more profitable?

Summary

How does Polyrizon compare to Heron Therapeutics?

Do institutionals & insiders hold more shares of HRTX or PLRZ?

Does the media favor HRTX or PLRZ?

Which has preferable earnings and valuation, HRTX or PLRZ?

Which has more volatility and risk, HRTX or PLRZ?

Is HRTX or PLRZ more profitable?

Do analysts prefer HRTX or PLRZ?

Summary

How does Polyrizon compare to Cognition Therapeutics?

Which has more risk & volatility, CGTX or PLRZ?

Does the media prefer CGTX or PLRZ?

Do analysts prefer CGTX or PLRZ?

Which has higher earnings & valuation, CGTX or PLRZ?

Is CGTX or PLRZ more profitable?

Do institutionals & insiders have more ownership in CGTX or PLRZ?

Summary

How does Polyrizon compare to PolyPid?

Is PLRZ or PYPD more profitable?

Do insiders and institutionals believe in PLRZ or PYPD?

Which has stronger earnings & valuation, PLRZ or PYPD?

Which has more risk and volatility, PLRZ or PYPD?

Do analysts prefer PLRZ or PYPD?

Does the media refer more to PLRZ or PYPD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools